Search
Obefazimod
go.drugbank.com/drugs/DB14828InvestigationalABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Categories: Heterocyclic Compounds, 2-RingUproleselan
go.drugbank.com/drugs/DB14829InvestigationalUproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
Categories: E-Selectin, antagonists & inhibitorsEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[L48181] Ritlecitinib is administered orally and is the first member of its class. … Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Synonyms: 2-propen-1-one, 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-D)pyrimidin-4-ylamino)-1-piperidinyl)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPyrotinib
go.drugbank.com/drugs/DB14993InvestigationalPyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Categories: Heterocyclic Compounds, 2-RingDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalDaridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. … It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[L10169] It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. … trial whose tumour is entirely or partially destroyed by a drug.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexMipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Synonyms: (3.BETA.)-CHOLEST-5-EN-3-YL 3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)PYRIDIN-4-YL CARBONATE, CHOLEST-5-EN-3-OL (3.BETA.)-, 3-(3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)-4-PYRIDINYL CARBONATE)Categories: P-glycoprotein substratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors